<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Aberrant promoter hypermethylation is a mechanism of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> suppressor gene inactivation </plain></SENT>
<SENT sid="1" pm="."><plain>We explored aberrant promoter hypermethylation of multiple genes in 88 human <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo> virus (HIV)-non Hodgkin <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (NHL), 25 post-transplant <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo> (PTLD) and five common variable <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo> (CVI)-related NHL </plain></SENT>
<SENT sid="2" pm="."><plain>Twenty-six of 79 (32.9%) HIV-NHL, eight of 14 (57.1%) PTLD and two of five (40.0%) CVI-NHL showed aberrant hypermethylation of O6-methylguanine-DNA methyltransferase (MGMT) </plain></SENT>
<SENT sid="3" pm="."><plain>Aberrant hypermethylation of <z:hpo ids='HP_0011420'>death</z:hpo>-associated protein-kinase (DAP-K) occurred in 70 of 84 (83.3%) HIV-NHL, 19 of 25 (72.0%) PTLD and three of five (60.0%) CVI-NHL </plain></SENT>
<SENT sid="4" pm="."><plain>These data implicate MGMT and DAP-K hypermethylation in <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">lymphomagenesis</z:e> of immunodeficient hosts </plain></SENT>
<SENT sid="5" pm="."><plain>In particular, promoter hypermethylation of DAP-K represents the most frequent molecular alteration yet identified in <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo>-related <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
</text></document>